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Abstract. Biogenic amines are integral part of nearly every cell. In the present 
study, the method of acidic extraction of histamine (His), of polyamines 
putrescine (Put), spermidine (Spd) and catecholamines epinephrine (Epi) and 
norepinephrine (NE) from human serum, precolumn derivatization with dansyl 
chloride, and LC/DAD analysis of the biogenic amines was used with the aim 
of monitoring differences of their levels in patients with diabetes mellitus, 
chronic urticaria, and Hashimoto's thyroiditis, compared to healthy subjects, 
and to observe them as possible markers for immune mediated diseases. The 
retention times were used for the determination of serum biogenic amines. Sta-
tistically significant differences were found in the levels of putrescine and hist-
amine in diabetes mellitus patients, of the levels of putrescine, histamine, sper-
midine and epinephrine in chronic urticaria patients and of the levels of put-
rescine and spermidine levels in Hashimoto's thyroiditis patients, compared to 
those of healthy controls. Norepinephrine was found only in the serum of pati-
ents with chronic urticaria. The values of recovery, evaluated in controls, 
varied between 85.7 and 106.7 %. The statistically significant changes in put-
rescine, histamine, spermidine and epinephrine levels in patients compared 
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with those in healthy people reflects the existence of biochemical disturbances 
in the mentioned immune-mediated diseases. 
Keywords: biogenic amines; serum; immune-mediated diseases; markers, 
LC/DAD. 
INTRODUCTION 
Polyamines and catecholamines are members of a broad group of the 
so-called biogenic amines.1 Since the first description (by Antoni van Leeu-
wenhoek in 1678) of crystals that were much later identified as polyamine salts, 
these molecules have been the subject of intense research efforts, which have 
shed light on several biological and pathological processes, for example the 
repair of the extracellular matrix, cell adhesion, synthesis of nucleic acids, and 
involvement in cellular growth and proliferation. These molecules are also rel-
ated with several types of cancer, such as breast and colon cancer, adenocar-
cinoma, non-Hodgkin’s lymphoma etc.2,3 Histamine and the polyamines putres-
cine and spermidine form a group of naturally occurring compounds that exert a 
large number of biological effects, but the mode of action of these biogenic 
amines at the molecular level is largely unknown.4–7 
Catecholamines – epinephrine and norepinephrine containing an amino func-
tion on a side chain together with the catechol function (i.e. hydroxyl groups at 
the 3- and 4-positions on a benzene ring) play an important role in the nervous, 
cardiovascular and endocrine systems. Catecholamines act via adrenergic recep-
tors, and are involved in the regulation of the response to stress, psychomotor 
activity, emotional processes, learning, sleep, and memory.1,8–12 Norepinephrine 
is also useful in the diagnosis of pheochromocytoma.13  
Polyamines as polycations are essentially involved in cell growth and differ-
entiation.14,15 They influence the transcriptional and translational stages of pro-
tein synthesis, stabilize membranes, modulate neurophysiological functions and 
may act as intracellular messengers.2,4 Hence, the majority of the polyamines 
will be sequestrated in some way and it is probable that only the “free” poly-
amine pool is physiologically active.16 Since intracellular polyamine concentra-
tions are much greater than extracellular, a small amount of cell lysis can 
markedly alter their obtained values.17  
Polyamines appear to have a role in immune-mediated diseases18 and have 
effect on DNA/RNA structure, chromatin condensation, translation, protein syn-
thesis and mammalian cell growth.19 In humans, the inhibitor of polyamine bio-
synthesis, α-difluoromethylornithine (DFMO), with an inhibitor of cyclooxygen-
ase 2 (COX-2) proved to be effective in prevention of the recurrence of colon 
cancer and adenomas, associated with the development of colon cancer.19 Ace-
tylated spermine is increased in urine in different types of human cancers.19 In 
colon cancer, the sensitivity of the detection of diacetylspermine (DiAcSpm) in 
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urine is much higher and in breast cancer noticeably higher than the sensitivity of 
regularly used diagnostic serum biomarkers.20  
Quantification of biogenic amines in biological fluids has an important diag-
nostic implication in medicine,21 but direct determination of biogenic amines in 
biological fluids is difficult because they are small aliphatic or aromatic mole-
cules that do not exhibit any structural features that would allow sensitive and 
selective detection.22 Chromatographic methods are generally used for the deter-
mination of biogenic amines, but, since only few of them absorb in the UV–vis-
ible region, for their simultaneous determination, a pretreatment step of derivat-
ization is generally performed.23 Among a wide panel of analytical methods 
developed for the quantification of biogenic amines, HPLC separation after deri-
vatization with dansyl chloride remains the most commonly used method.24 In 
this study, pre-column derivatization, gradient elution, and ultraviolet detection 
with a DAD detector were used.  
First, the serum levels of specific biogenic amines in three immune-mediated 
diseases, i.e., diabetes mellitus, chronic urticaria and Hashimoto's thyroiditis, 
were investigated to elucidate whether there were any changes in their levels in 
mentioned diseases compared to healthy people. In order to determine the con-
centrations of serum biogenic amines in these diseases and to assess the differ-
ences among their levels,19,24,25 the method of Ben-Gigirey et al. modified by 
Mao et al. was used because equipment similar to theirs was available, thereby 
providing reproducible results. 
MATERIALS AND METHODS 
Reagents and chemicals 
All chemicals were of analytical HPLC grade. All biogenic amine standards were pur-
chased as hydrochloride salts of the highest available purity. The standards of 1,4-diam-
inobutane dihydrochloride (putrescine), 99+ %, spermidine trihydrochloride, 99+ %, hista-
mine dihydrochloride, 99 %, and L-(–)-epinephrine, 99 %, were purchased from Acros Org-
anics (Beel, Belgium). (–)-Norepinephrine, 99.5 %, was purchased from Sigma (St Louise, 
MO, USA). The derivatization reagent, dansyl chloride, 98%, was procured from Acros 
Organics. Perchloric acid, sodium hydroxide, sodium bicarbonate, 25 % ammonium hydro-
xide, acetone, acetonitrile, and ammonium formate were from Merck (Darmstadt, Germany). 
Ultra-pure HPLC grade water was prepared by passing doubly deionized water through a 
Milli-Q system.  
Individual standard solutions of the biogenic amines were made by dissolving an exactly 
weighed amount of the required standard in ultra-pure water. After dissolution, each standard 
was diluted to 1 mg L-1 with ultra-pure water and stored as a stock solution at 4 °C in the dark. 
Working standard dilutions were freshly prepared by diluting the stock standard solutions with 
ultra-pure water for each assay. A solution of dansyl chloride (the derivatization reagent) was 
made in acetone, diluted to 10 mg L-1 and then stored at 4 °C in the dark.  
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Serum preparation 
Whole blood was collected after venipuncture in covered red top test tubes – Vacutainers 
(BD – Becton Dickinson), without any anticoagulant. After collection of whole blood, the 
blood was left undisturbed to clot for 15–30 min at room temperature. The clot was removed 
by centrifuging at 2000g for 10 min. The resulting supernatant was designated serum. 
Following centrifugation, the liquid component (serum) was immediately transferred into a 
clean polypropylene tube using a Pasteur pipette. The serum samples were apportioned into 
0.5 mL aliquots and stored at –20 °C until analysis.  
Patients’ characteristics 
The present study included patients from the University Clinical Centre “Zvezdara” 
Hospital (Belgrade, Serbia) or the Clinical Centre of Serbia (Belgrade, Serbia) and 20 healthy 
controls. Three medical conditions/diseases – diabetes mellitus (Type I and Type II), chronic 
urticaria and Hashimoto's thyroiditis, which were newly diagnosed, were investigated in the 
serum. 12 of 20 diabetes mellitus patients were men, and 8 were women (age range 53–64, 
median age 59); 6 of 20 chronic urticaria patients were men, and 14 were women (age range 
24–77, median age 48), and 8 Hashimoto's thyroiditis patients were women (age range 33–75, 
median age 48). The chosen patients had no additional disorders beside the investigated one. 
Healthy controls, of which 11 women and 9 men (age range 27–62, median age 36), were ran-
domly chosen and did not have any reported diagnosis. All patients and controls provided 
written informed consent before entry into the study.  
Apparatus 
The HPLC system comprises a liquid chromatograph Agilent 1200 Series (Agilent Tech-
nologies, Santa Clara, CA, USA), with a degasser, a binary pump, an autosampler, a column 
compartment equipped with a Zorbax Eclipse Plus C18 column (150 mm×4.6 mm; 5 μm), and 
a diode-array detector (DAD). A personal computer system running ChemStation Software 
(Agilent Technologies, Santa Clara, CA, USA) was used for data collection and processing. 
Chromatographic conditions 
A mixture of solvents A (water containing 5 mM ammonium formate) and B (aceto-
nitrile) in a gradient mode of elution was used as the mobile phase. The gradient program was 
selected as follows: 55–65 % B, 0–6 min; 65–100 % B, 6–15 min; 100 % B, 15–19 min; 100– 
–65 % B, 19–20 min; 65 % B, 20–24 min. The mobile phase solutions were pumped at a flow 
rate of 1.0 mL min-1. Signals were accumulated in the wavelength range 190–450 nm using a 
DAD, and the chromatograms were recorded at 254 nm. The injection volume was 50 µL. The 
temperature of the column was kept at 40 °C. 
Standard treatment 
The stock standard solutions of each biogenic amine were diluted with ultra pure water 
to the desired concentrations. Each standard (500 µL) was worked up as described above for 
the serum samples. The qualitative analysis was realized using the retention times. The quan-
titative analysis was performed using the corresponding external calibration. The calibration 
curves were obtained by plotting the biogenic amines peak area values against the respective 
concentrations of biogenic amines standards. 
Sample preparation 
The method proposed by Mao et al. was used.25 To 500 µL of serum sample in a micro 
test tube, 750 µL of 0.4 M perchloric acid was added, then vortexed for 1 min, and centrifuged 
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at 13000 rpm for 10 min. The supernatant was aspirated into another test tube followed by the 
addition of 67.5 µL of 2.0 M NaOH, vortexed for 1 min and then 150 µL of a saturated sol-
ution of sodium bicarbonate was added into the test tube to adjust the pH to 8.0–8.5. To a 
prepared sample 1000 µL of 10 g L-1 dansyl chloride was added, and the mixture was 
vortexed for 1 min, and left to react in a closed water bath at 40 °C for 45 min. Finally, 50 µL 
of 25 % ammonium hydroxide was added to remove the excess derivatization reagent, and 
incubated for 30 min, at room temperature, in the dark. Before injection, all samples were 
filtrated through 0.40 µm Econofilters. 
Validation of the method 
All quantitative analysis were performed by the external calibration procedure using 
standard solutions of putrescine, histamine, spermidine, epinephrine and norepinephrine. The 
validation of the method was accomplished by the test of linearity, precision and accuracy, 
limit of detection (LOD), limit of quantification (LOQ) and recovery. The linearity of the 
method was tested for the biogenic amine standards by injecting 50 µL of each amine standard 
solution within the concentration range of 5–50×103 ng L-1 into the LC/DAD system. The 
accuracy of this analytic method was assessed as the percentage relative error. The LOD and 
LOQ values for the biogenic amines were determined by injecting progressively lower con-
centration of the standard solution under the chromatographic conditions. The recovery study 
was performed using a real serum sample from a healthy control, by spiking techniques. This 
control serum sample was treated in the same way as were the other samples. The recoveries 
were checked as three different concentration levels (low, medium and high). 
Statistical analysis 
Descriptive statistics and the Kruskal–Wallis test together with the multiple-comparison 
Z-value test were used for statistical analysis of the experimental data employing a demo 
version of the Number Cruncher Statistical Systems software (Kaysville, UT, USA). The 
linear relationship between peak areas and concentrations was calculated by linear regression. 
RESULTS AND DISCUSSION 
Optimal conditions of sample processing 
The acidic precipitation/extraction procedure is the most promising method 
for complete recovery of low molecular weight compounds from complex mat-
rices.1 A solution of 0.4 M HClO4 gave slightly sharper peaks for the biogenic 
amines in the chromatograms, which is in agreement with the work of Mao et al.25 
Linearity 
Least-square regression was used for the determination of the slope, inter-
cept, and the correlation coefficient of the calibration curves, constructed by plot-
ting the peak area values against the respective concentrations. Linearity was 
obtained for the range of 80–5×104 ng L–1 (Fig. S-1 of the Supplementary mat-
erial to this paper) and the correlation coefficients were excellent (Table S-I of 
the Supplementary material). 
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Precision and accuracy 
The repeatability was evaluated by analyzing the quality control samples, at 
three different concentrations, six times per day. The intermediate precision was 
evaluated by analyzing the same samples once daily for two days. The relative 
standard deviation (RSD) of the concentrations obtained from the corresponding 
calibration curves was taken as the precision. The results, which are summarized 
in Table S-II of the Supplementary material, meet the requirements of accuracy 
within 95.12–99.75 %, and the precision RSD values were ≤ 8.46 %. 
Limits of detection (LOD) and quantification (LOQ) 
The lowest concentrations assayed where the signal/noise ratio was at least 
10:1 was regarded as the LOQ. The LOD was defined as the concentration when 
the signal/noise ratio was 3:1. 
The determined LOD values were 40 ng L–1 for putrescine, 30 ng L–1 for 
histamine, 250 ng L–1 for spermidine, 90 ng L–1 for epinephrine and 596 ng L–1 
for norepinephrine. 
The determined LOQ values were 150 ng L–1 for putrescine, 90 ng L–1 for 
histamine, 820 ng L–1 for spermidine, 300 ng L–1 for epinephrine and 1980 ng L–1 
for norepinephrine. 
Recovery experiment 
Serum samples with known concentrations of biogenic amines, were spiked 
with concentrations of putrescine and histamine (1000, 1500 and 2000 ng L–1), 
spermidine (2000, 4000 and 6000 ng L–1), epinephrine (350, 700 and 1000 ng L–1), 
and norepinephrine (1500, 3000 and 5000 ng L–1). The serum concentration of 
each biogenic amine was determined five times, and the recovery rate of each 
standard was calculated. The chromatogram of a spiked serum sample is pre-
sented in Fig. S-2 of the Supplementary material. The average recovery rate 
ranged from 85.7 to 106.7 %.  
The obtained data (Table S-III of the Supplementary material) showed good 
recovery values for all the investigated biogenic amines. 
Detection of the levels of the biogenic amine in the serum of the controls and 
patients 
A chromatogram of a mixture of the standard biogenic amines is shown in 
Fig. 1. All the standard amine peaks, under the given experimental conditions, 
appeared within 20 min, without overlapping. The retention times were 8.9 min 
for putrescine, 10.1 min for histamine, 13.1 min for spermidine, 13.9 min for 
norepinephrine and 14.7 min for epinephrine. 
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Fig. 1. A chromatogram of a mixture of the investigated serum biogenic amines. 
The peaks of the investigated biogenic amines in the serum samples could 
also be separated within 20 min. Occasionally, the recording was spoiled by 
residues of the protein precipitate passing through the filter. This was resolved by 
additional centrifugation of the sample. Representative chromatograms of bio-
genic amines in the sera of the control subjects and patients with the investigated 
diseases are shown in Fig. 2. 
The concentration levels for the five serum biogenic amines, determined in 
controls, and in patients are given in Table I. Differences, observed by para-
meters of descriptive statistics, were evaluated by the Kruskal–Wallis test fol-
lowed by the multiple-comparison Z-value test. The putrescine concentrations in 
the sera of patients with diabetes mellitus, chronic urticaria and Hashimoto's 
thyroidits patients were lower compared to those in the sera of the healthy con-
trols (P < 0.0001 and Z: C(D,U,H). The histamine levels were also statistically 
significant different between healthy controls and patients with diabetes mellitus 
or chronic urticaria (P < 0.0001 and Z: D(C,H,U)), while patients with diabetes 
had higher histamine levels than healthy subjects (P < 0.0001). Unexpectedly, in 
serum of chronic urticaria patients, the histamine levels were lower than in healthy 
controls (P < 0.0001). Eight patients with Hashimoto’s thyroiditis had detectable 
histamine in their serum, of which four values were the same as in the sera of the 
healthy controls, while the other four were lower. The histamine levels in the sera 
of patients with Hashimoto's thyroiditis were also lower compared to those in the 
sera of patients with diabetes mellitus (P < 0.0001). Spermidine levels in the serum  
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Fig. 2. Representative chromatograms of serum biogenic amines in: A) healthy controls, B) 
diabetes mellitus patients, C) chronic urticaria patients and D) Hashimoto's thyroiditis patients. 
TABLE I. Obtained values (in ng L-1 ± SD) for the five serum biogenic amines in healthy 
controls, diabetes mellitus patients, chronic urticaria patients and patients with Hashimoto's 
thyroiditis; SD is the standard deviation of six replicate determinations; C = healthy controls, 
D = diabetes mellitus, U = chronic urticaria and H = Hashimoto’s thyroiditis patients 
Analyte Controls (n = 20) 
Diabetes 
mellitus 
(n = 20) 
Chronic 
urticaria 
(n = 20) 
Hashimoto's 
thyroiditis 
(n = 8) 
P-valuea Z-valuea 
Putrescine 1715±280 230±60 450±50 255±110 <0.0001 C(D,U,H) 
Histamine 285±110 505±230 140±60 165±139 <0.0001 D(C,H,U) 
Spermidine 855±180 1205±310 1825±580 1165±410 <0.0001 C(D,U,H) 
Epinephrine 382±60 490±140 965±510 395±180 <0.0001 U(D,H,C) 
Norepinephrine – – 700±40 – – – 
aResults of the statistical Kruskal–Wallis test with the multiple-comparison Z-value test 
of patients with diabetes mellitus, chronic urticaria and Hashimoto's thyroiditis 
were higher in comparison with those for the healthy controls (P < 
< 0.0001; Z: C(D,U,H)). The epinephrine levels between chronic urticaria patients 
and healthy controls, diabetes mellitus and Hashimoto's thyroiditis patients were 
also statistically significantly different (P < 0.0001; Z: U(D,H,C)). The chronic 
urticaria patients had higher concentrations of serum epinephrine compared to 
those of the controls (P < 0.0001). Norepinephrine (a hormone related to stress) 
was detected only in the serum of chronic urticaria patients. 
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The findings of enhanced histamine levels in diabetes mellitus patients are in 
agreement with the work of Gill et al.26 who also found increased histamine 
concentrations in the plasma of patients suffering from diabetes mellitus (types I 
and II). Moreover, the studies of Inui et al.27 and of Alkan et al.28 performed on 
rats and mice, respectively, support the notion that endogenous histamine is 
involved in the pathogenesis of diabetes. 
The detection of norepinephrine only in the serum of chronic urticaria pati-
ents is in agreement with literature data that patients with adrenergic urticaria 
have enhanced levels of serum catecholamines.29 As there were no pre-analytical 
patients (or healthy control subjects) prepared for venipuncture, it could be con-
cluded that enhanced levels of serum catecholamines are specific only for pati-
ents with chronic urticaria. 
A possible reason why the obtained values were in disagreement with those 
of Mao et al.25 might be the influence of nutritive habits on the level of biogenic 
amines in body fluids, i.e., blood. Patients with chronic urticaria might have a 
pseudo-allergic reaction (so-called exogenic allergy) caused by biogenic amines 
(histamine) from food such as canned fish.30,31 
In clinical practice, it was recognized that patients with chronic urticaria and 
Hashimoto’s thyroiditis diseases were alike and very often followed each other.33 
This could be one of the reasons why the spectra of these two diseases were 
similar. In patients with Hashimoto’s thyroiditis, autoimmune urticaria might 
appear and vice versa, and for this reason clinicians examined whether Hashi-
moto’s thyroiditis occurs in patients with chronic urticaria.33,34 
CONCLUSIONS 
In this study, the levels of putrescine, histamine, spermidine, epinephrine, 
and norepinephrine in serum of healthy subjects and patients with different 
immune-mediated disease were investigated for the first time. It was found that 
the quantities of serum biogenic amines statistically differed in diabetes mellitus, 
chronic urticaria and Hashimoto’s thyroiditis patients, compared to healthy sub-
jects.  
To the best of our knowledge, there is no report on the analysis of the levels 
of biogenic amines in the serum of patients with chronic urticaria or Hashimoto’s 
thyroiditis. Contrary to expectations, it was found that the histamine levels were 
not elevated in the sera of chronic urticaria patients, compared to those in normal 
subjects. Furthermore, it was noticed that the values of norepinephrine and 
epinephrine were increased in patients with chronic urticaria and hence, it is 
assumed that the human organism produces higher amounts of these substances 
as a natural defense against anaphylaxis, and simultaneously suppresses the 
histamine level. Higher levels of spermidine were noticeable within all three 
investigated immune-mediated conditions compared to within healthy controls. 
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The putrescine levels in all three immune-mediated disorders were lower than in 
healthy subjects. Therefore, observation of the levels of spermidine and 
putrescine might be used as a non-specific marker that indicates that some health, 
possibly immune-mediated, disorder is occurring in the body. 
The presented results hint on biogenic amines as possible autoimmune 
disease markers, and some future studies could be designed for closer inves-
tigations. The possible influence of nutrition habits on the levels of biogenic 
amines in blood serum could also be the subject of some future studies. 
SUPPLEMENTARY MATERIAL 
The results of the calibration and validation of the developed method are available 
electronically from http://www.shd.org.rs/JSCS/, or from the corresponding author on request.  
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И З В О Д  
ОДРЕЂИВАЊЕ БИОГЕНИХ АМИНА LC/DAD МЕТОДОМ У СЕРУМУ ПАЦИЈЕНАТА 
СА ДИЈАГНОЗОМ Diabetes mellitus, ХРОНИЧНА Urticaria ИЛИ ХАШИМОТОВ 
ТИРОИДИТИС 
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3Центар за експерименталну онкологију, Институт за онкологију и радиологију, 11000 Београд, 
4Институт за алергологију и имунологију, Клинички центар Србије, Медицински факултет, 
Универзитет у Београду, Др Суботића 13, 11000 Београд, 5Институт за ендокринологију, Клинички 
центар Србије, Др Суботића 13, 11000 Београд, 6Клиника за ендокринологију, Универзитетски 
клинички центар „Звездара“, Димитрија Туцовића 161, 11000 Београд и 7Центар за хемију - 
Институт за хемију, технологију и металургију, Универзитет у Београду, 
Његошева 12, 11000 Београд 
Биогени амини су саставни део готово сваке ћелије. Хистамин (His), полиамини 
путресцин (Put) и спермидин (Spd), катехоламини адреналин (Epi) и норадреналин (NE) 
изоловани су из људског серума методом киселе естракције. Преколонска дериватиза-
ција је урађена помоћу данзил-хлорида, а затим је уследила LC/DAD анализа биогених 
амина у циљу утврђивања разлика у њиховим нивоима код пацијената са дијагнозом 
diabetes mellitus, хронична urticaria или Хашимотов тироидитис, у односу на здраве 
контроле, али и утврђивања њихове функције као могућих маркера за имуно-посредо-
ване болести. За одређивање серумских биогених амина коришћена је метода ретен-
ционих времена. Утврдили смо да постоји статистички значајна разлика у нивоима пут-
ресцина и хистамина код пацијената са дијагнозом diabetes mellitus, путресцина, хиста-
мина, спермидина и епинефрина код пацијената са дијагнозом хронична urticaria и пут-
ресцина и спермидинa код пацијената са дијагнозом Хашимотов тироидитис, у поре-
ђењу са здравим контролама. Норепинефрин је детектован једино код пацијената са 
дијагнозом хронична urticaria. Вредности повратног приноса измерене у контролама 
 LC/DAD DETERMINATION OF BIOGENIC AMINES 497 
кретале су се у опсегу 85,7–106,7 %. Посматрање нивоа спермидина и путресцина би 
могло да се користи као неспецифични индикатор који показује да се неки биохемијски, 
могуће имунo-посредован, здравствени поремећај дешава у телу. 
(Примљено 10. септембра 2015, ревидирано 28. фебруара, прихваћено 29. фебруара 2015) 
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